Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
Sector: Biotechnology
Industry: Biotechnology
Lyra Therapeutics, Inc.
Nasdaq bars a compliance period at 1:250
- 1:50Reverse splitMay 28, 202550 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $398K | $1.53M | $1.56M | $1.36M | $285K | $0 | $0 | $1.24M |
| YoY Growth | -74.1% | -1.5% | 14.3% | 378.2% | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $29.69M | $12.52M | $0 | $0 |
| Gross Profit | $398K | $1.53M | $1.56M | $1.36M | -$29.41M | -$12.52M | $0 | $1.24M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -10318.9% | - | - | 100.0% |
| Research and Development | $18.41M | $43.77M | $48.03M | $38.8M | $29.69M | $12.52M | $12.03M | $4.97M |
| Selling, General, and Administrative | $11.54M | $18.5M | $19.06M | $17.56M | $14.21M | $9.69M | $4.49M | $3.53M |
| Other | $0 | $35.62M | $1.59M | $1.32M | -$29.69M | -$12.52M | -$1 | $0 |
| Total Operating Expenses | $29.95M | $97.88M | $68.68M | $57.67M | $14.21M | $9.69M | $16.52M | $8.5M |
| Operating Income (EBIT) | -$31.02M | -$96.35M | -$67.12M | -$56.31M | -$43.62M | -$22.21M | -$16.52M | -$7.26M |
| Operating Margin | -7794.5% | -6280.8% | -4308.1% | -4131.0% | -15303.5% | - | - | -583.5% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $1.13M | $2.95M | $4.5M | $1.04M | $102K | $82K | $213K | $36K |
| Other Income (Expense) | $2.11M | $2.95M | $4.5M | $1.04M | $102K | $82K | $213K | $1.23M |
| Income Before Tax (EBT) | -$28.91M | -$93.4M | -$62.62M | -$55.27M | -$43.51M | -$22.13M | -$16.31M | -$6.03M |
| Income Tax Expense | $11K | $39K | $59K | $13K | $0 | $0 | $0 | $0 |
| Net Income | -$28.92M | -$93.44M | -$62.68M | -$55.28M | -$43.51M | -$22.13M | -$16.31M | -$6.03M |
| Net Income Margin | -7266.1% | -6090.9% | -4023.1% | -4055.6% | -15267.7% | - | - | -484.6% |
| Supplementary Data | ||||||||
| EPS | -18.62 | -1.43 | -1.26 | -1.83 | -3.35 | -2.59 | -62.50 | -0.98 |
| Diluted EPS | -18.62 | -1.43 | -1.26 | -1.83 | -3.35 | -2.59 | -62.50 | -0.98 |
| Weighted Average OS | 15.53M | 65.11M | 49.75M | 30.24M | 12.99M | 8.55M | 8.18M | 6.27M |
| EBITDA | -$29.09M | -$60.26M | -$65.25M | -$53.92M | -$42.61M | -$22.11M | -$16.49M | -$7.18M |
| EBITDA Margin | -7310.1% | -3928.4% | -4188.1% | -3956.2% | -14952.3% | - | - | -576.9% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $15.89M | $40.58M | $22.35M | $32.55M | $45.75M | $74.59M | $9.81M | $23.89M |
| Short-Term Investments | $0 | $0 | $80.4M | $65.34M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $15.89M | $40.58M | $102.75M | $97.89M | $45.75M | $74.59M | $9.81M | $23.89M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $167K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $379K | $2.45M | $2.07M | $2.94M | $0 | $0 | $0 | $0 |
| Total Current Assets | $16.27M | $43.02M | $104.82M | $100.83M | $47.92M | $75.92M | $10.12M | $24.93M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $17.84M | $21.33M | $35.28M | $4.47M | $5.86M | $4.47M | $3.42M | $103K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $1.99M | $1.39M | $0 | $0 | $0 | $329K | $329K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.99M | $0 | $1.11M | $4.67M | $1.09M | $447K | $1.1M | $0 |
| Total Long-Term Assets | $19.84M | $23.32M | $37.78M | $9.14M | $6.95M | $4.91M | $4.84M | $432K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $36.11M | $66.35M | $142.6M | $109.97M | $54.87M | $80.83M | $14.96M | $25.36M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $663K | $1.18M | $3.13M | $2.62M | $3.13M | $922K | $1.07M | $631K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $11.86M | $398K | $1.66M | $1.27M | $9.79M | $0 | $3.13M | $0 |
| Other Current Liabilities | -$7.82M | $4.82M | $1.23M | $659K | $633K | $149K | -$3.02M | $845K |
| Total Current Liabilities | $9.52M | $12.63M | $19.6M | $14.47M | $18.25M | $4.88M | $5.21M | $1.96M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $11.86M | $12.14M | $14.08M | $1.93M | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $11.86M | $0 | $0 | $0 | $0 | $0 | $0 | $130.47M |
| Total Long-Term Liabilities | $37.3M | $42.12M | $33.58M | $14.74M | $2.31M | $1.45M | $2.43M | $130.47M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $46.83M | $54.75M | $53.18M | $29.21M | $20.55M | $6.34M | $7.63M | $132.43M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $130.67M | $130.35M |
| Common Stock | $2K | $65K | $57K | $32K | $13K | $13K | $6K | $6K |
| Retained Earnings | -$433.71M | -$404.79M | -$311.36M | -$248.68M | -$193.4M | -$149.88M | -$127.76M | -$111.45M |
| Comprehensive Income & Other | $0 | $0 | $33K | $10K | $0 | -$0 | $0 | -$2.8M |
| Other Stockholders' Equity | $422.99M | $416.32M | $400.72M | $329.4M | $227.7M | $224.36M | $135.08M | $4.37M |
| Total Equity | -$10.72M | $11.59M | $89.42M | $80.75M | $34.32M | $74.49M | $7.33M | -$107.07M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $36.11M | $66.35M | $142.6M | $109.97M | $54.87M | $80.83M | $14.96M | $25.36M |
| Supplementary Data | ||||||||
| Total Debt | $30.26M | $34.38M | $26.88M | $4.18M | $1.45M | $2.44M | $3.33M | $0 |
| Net Debt | $14.37M | -$6.2M | $4.53M | -$28.37M | -$44.29M | -$72.15M | -$6.48M | -$23.89M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$28.92M | -$93.44M | -$62.68M | -$55.28M | -$43.51M | -$22.13M | -$16.31M | -$6.03M |
| Depreciation & Amortization | $459K | $471K | $278K | $1.07M | $1M | $95K | $27K | $82K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$2.42M | $0 | $0 | $0 |
| Stock-Based Compensation | $2.33M | $6.72M | $5.89M | $5.45M | $2.77M | $1.81M | $244K | $406K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $164K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$516K | -$1.89M | $450K | -$2.41M | $2.35M | $345K | -$205K | $134K |
| Other Working Capital | -$2.21M | -$4.46M | -$5.33M | $6.97M | $11.57M | -$1.22M | $2.32M | -$55K |
| Total Working Capital Change | -$2.73M | -$6.35M | -$4.88M | $4.55M | $13.92M | -$879K | $2.11M | $79K |
| Other Non-Cash Items | -$8K | $22.58M | -$1.9M | $824K | $2.42M | -$45K | $167K | -$1.18M |
| Net Cash from Operating | -$28.86M | -$70.01M | -$63.3M | -$43.38M | -$25.82M | -$21.14M | -$13.75M | -$6.64M |
| Investing Activities | ||||||||
| Capital Expenditures | -$116K | -$2.34M | -$1.05M | -$164K | -$3.38M | -$1.77M | -$211K | -$37K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$47.95M | -$122.42M | -$64.84M | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $130.59M | $110.89M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $18K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$98K | $80.31M | -$12.58M | -$65.01M | -$3.38M | -$1.77M | -$211K | -$37K |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | -$500K |
| Common Stock Issuance | $5M | $8.82M | $69.24M | $100.5M | $604K | $59.89M | $111K | $12K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$726K | -$287K | -$3.55M | -$4.24M | -$245K | -$2.58M | -$226K | $28.71M |
| Net Cash from Financing | $4.27M | $8.53M | $65.69M | $96.26M | $359K | $87.7M | -$115K | $29.21M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$24.68M | $18.82M | -$10.2M | -$12.13M | -$28.85M | $64.78M | -$14.08M | $22.54M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$28.86M | -$70.01M | -$63.3M | -$43.38M | -$25.82M | -$21.14M | -$13.75M | -$6.64M |
| Capital Expenditure | -$116K | -$2.34M | -$1.05M | -$164K | -$3.38M | -$1.77M | -$211K | -$37K |
| Free Cash Flow | -$28.98M | -$72.35M | -$64.35M | -$43.55M | -$29.2M | -$22.92M | -$13.96M | -$6.68M |
| Cash at Beginning | $42.57M | $23.75M | $33.94M | $46.08M | $74.92M | $10.14M | $23.89M | $1.68M |
| Cash at End | $17.89M | $42.57M | $23.75M | $33.94M | $46.08M | $74.92M | $9.81M | $24.22M |